Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

dna sequences visualised with huv transiluminatorPlasmodium vivax is the world's most widely distributed human malaria parasite. Estimates suggest that 2.5 billion people are at risk of infection and nearly 400 million clinical episodes occur annually. P. vivax endemicity is highest in Asia and Asia-Pacific, which contribute 84% of the global population at risk, or 2 billion people. Infection is also endemic in the Americas. As yet, there is no licensed vaccine and no other vaccine candidate in development that could prevent malaria infection. Our research group has been collaborating with Dr Lilia González-Cerón at the Centro Regional de Investigación en Salud Pública (CRISP) and Instituto Nacional de Salud Pública(INSP) , who has collaborated with us to assess immune responses against isolates of the P. vivax parasite from Mexico.